Last edition
News about "Pertuzumab biosimilar "
EirGenix Signs Second Global Licensing Deal With Sandoz for Pertuzumab Biosimilar
EirGenix Inc., a Taiwan-based biopharmaceutical and CDMO company, has signed a second global exclusive licensing agreement with Sandoz AG for the commercialization of its pertuzumab biosimilar EG1206A, developed as an alternative to Roche’s Perjeta.
Pertuzumab Biosimilar | 14/11/2025 | By Darshana
Zydus and Dr. Reddy to Co-Market Pertuzumab Biosimilar in India
Zydus Lifesciences and Dr. Reddy’s Laboratories Ltd. have announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India.
Pertuzumab Biosimilar | 05/07/2024 | By Aishwarya | 1458
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy